Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
Investing.com -- Zoetis Inc. shares surged 9.4% premarket on Tuesday after the company reported second-quarter earnings that exceeded analyst expectations and raised its full-year guidance, demonstrating strong momentum across its diverse product portfolio.
The company reported adjusted earnings per share of $1.76 for the second quarter, significantly beating the analyst estimate of $1.62. Revenue came in at $2.46 billion, above the consensus estimate of $2.41 billion and representing a 4% increase compared to the same quarter last year. On an organic operational basis, revenue grew 8% YoY.
"Zoetis delivered a strong broad-based performance in the second quarter of 2025, with 8% organic operational revenue growth," said Kristin Peck, Chief Executive Officer of Zoetis. "Our consistent results across economic and competitive cycles reflect the strength of our innovation engine, the breadth of our diversified portfolio and the discipline of our execution."
In the U.S. segment, revenue reached $1.4 billion, increasing 4% compared to the second quarter of 2024, with companion animal products growing 9%, driven primarily by Simparica Trio and the company’s dermatology portfolio. International segment revenue rose 3% to $1.1 billion, with companion animal products growing 8% on both a reported and operational basis.
The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing organic operational growth of 6.5% to 8.0%. This outlook exceeds the consensus estimate of $9.497 billion. Zoetis also increased its adjusted EPS guidance to $6.30-$6.40, above analyst expectations of $6.21.
The improved outlook reflects Zoetis’ strong first-half performance, disciplined execution, and effective cost management. The company continues to advance its product pipeline with new approvals and geographic expansions across both companion animal and livestock segments.